Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRoivant Sciences Ltd

Roivant Sciences Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
41.85 USD 0.66 ( 1.60%)
Last update at 2026-11-11T21:00:00Z
VOLUME
7890395
Market Cap
28531.76M

Momentum Score

…

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
40.92
Low
42.24
High
52 Week Price Range
14.50
Low
42.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
41.19
Dividend Yield
-
Revenue TTM
7.53M
Revenue Per Share
0.01
Gross Profit TTM
-723.89M
Debt / Equity
0.02
ROE
-8.52%
Net Debt
-1315.65M
ROCE
-4.86%
Diluted EPS TTM
-0.45

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -264.58M -681.59M 4567.86M -1224.83M -923.75M
Minority interest 98.14M 184.75M 117.72M -106.43M -78.85M
Net income -299.77M -171.98M 4348.93M -1230.02M -924.12M
Selling general administrative 610.47M 591.41M 416.13M 600.51M 775.03M
Gross profit 6.97M 28.14M 31.11M 48.15M 46.32M
Reconciled depreciation 3.35M 14.07M 22.04M 18.86M -
Ebit -264.58M -681.59M 4602.63M -1077.57M -1211.75M
Ebitda -261.23M -667.52M 4624.67M -1107.58M -1499.83M
Depreciation and amortization 3.35M 14.07M 22.04M -30.01M -288.08M
Non operating income net other - - - 56.45M -90.73M
Operating income -1285.30M -1113.68M -824.93M -1077.57M -1211.75M
Other operating expenses 1293.56M 1142.73M 857.64M 1138.85M 1267.03M
Interest expense - - 34.78M 27.97M 7.04M
Tax provision 133.33M 48.17M 22.22M 5.19M 0.37M
Interest income 178.11M 258.38M 146.43M 32.18M 0.37M
Net interest income 178.11M 258.38M 111.65M 4.22M -6.67M
Income tax expense 133.33M 48.17M 21.50M 5.19M 0.37M
Total revenue 8.26M 29.05M 32.71M 61.28M 55.29M
Total operating expenses 1292.28M 1141.82M 856.04M 1125.72M 1258.07M
Cost of revenue 1.28M 0.91M 1.60M 13.13M 8.97M
Total other income expense net 1020.73M 432.09M 5392.78M -147.26M 288.00M
Discontinued operations - - - 114.56M 114.56M
Net income from continuing ops -397.91M -729.76M 4231.21M -1230.02M -924.12M
Net income applicable to common shares - - - -1009.03M -845.26M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 5728.05M 5436.94M 7222.48M 2389.60M 2585.13M
Intangible assets - - 137.84M 144.88M -
Other current assets 81.86M 113.17M 72.69M 121.77M 82.22M
Total liab 435.63M 249.74M 773.95M 782.02M 546.19M
Total stockholder equity 4527.37M 4687.60M 5968.58M 1607.59M 2038.94M
Deferred long term liab - - - - 13.74M
Other current liab 206.41M 114.29M 177.00M 15.08M 128.24M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -501.81M 116.06M 576.17M -3772.75M -2763.72M
Other liab - - - 80.58M 66.83M
Other assets - - - 49.48M 25.82M
Cash 1423.09M 2715.41M 6535.71M 1676.81M 2060.40M
Total current liabilities 281.24M 149.41M 266.76M 272.45M 184.37M
Current deferred revenue - 1.17M 4.17M 167.13M 10.15M
Net debt -1315.65M -2615.24M -6035.96M -1195.41M -1776.51M
Short term debt 11.15M 9.84M 21.89M 52.41M 11.40M
Short long term debt - - 12.00M 40.72M -
Short long term debt total 107.44M 100.17M 499.75M 481.40M 283.89M
Other stockholder equity 5024.83M 4562.11M 5396.49M 5382.96M 4803.61M
Property plant equipment - - - 39.09M 25.91M
Total current assets 5167.38M 5000.06M 6731.83M 1798.59M 2146.52M
Long term investments 407.99M 302.94M 247.75M 304.32M 325.83M
Net tangible assets - - - 1012.88M 1679.43M
Short term investments 2872.60M 2171.48M 5.37M 15.30M 13.63M
Net receivables 789.84M - 82.81M 32.73M 6.73M
Long term debt - - 430.59M 375.51M 210.03M
Inventory - - 35.25M 2.76M -
Accounts payable 18.00M 23.69M 53.23M 37.83M 34.58M
Noncontrolling interest in consolidated entity - - - 449.82M 382.00M
Accumulated other comprehensive income 4.36M 9.44M -4.08M -2.62M -0.95M
Retained earnings total equity - - - -3772.75M -2763.72M
Non currrent assets other 33.02M 32.86M 39.11M 49.48M 25.82M
Non current assets total 560.66M 436.88M 490.65M 591.02M 438.61M
Capital lease obligations 107.44M 100.17M 57.16M 65.17M 73.87M
Long term debt total - - - 375.51M 210.03M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments -667.19M -1766.29M 5203.62M -44.27M 320.17M
Change to liabilities - - - 43.31M 83.97M
Total cashflows from investing activities -682.33M -1766.29M 5203.62M -44.27M 303.30M
Net borrowings 0.00M -52.75M -30.70M 129.75M 14.81M
Total cash from financing activities 134.24M -1219.79M 419.36M 499.46M 306.79M
Change to operating activities - - - 1.99M -6.27M
Net income -397.91M -356.73M 4231.21M -1115.46M -924.12M
Change in cash -1294.68M -3824.79M 4858.34M -381.92M -67.64M
Begin period cash flow 2725.66M 6550.45M 1692.12M 2074.03M 2141.68M
End period cash flow 1430.98M 2725.66M 6550.45M 1692.12M 2074.03M
Total cash from operating activities -750.35M -839.45M -765.27M -843.39M -677.73M
Issuance of capital stock 193.60M 112.78M 438.56M 379.71M 0.00M
Depreciation 3.35M 14.07M 22.04M 18.86M 5.93M
Other cashflows from investing activities -636.64M 110.47M 5241.99M -31.58M 0.56M
Dividends paid - - 6.00M 162.71M -
Change to account receivables -770.24M - - - -
Sale purchase of stock -319.50M -1293.23M 0.95M 0.32M -
Other cashflows from financing activities -9.37M 13.41M 17.51M 312.30M 328.38M
Change to netincome - - - 275.86M 222.31M
Capital expenditures 8.21M 4.60M 1.38M 12.69M 17.44M
Cash flows other operating - - - -65.97M -59.89M
Cash and cash equivalents changes - - - -388.20M -67.64M
Change in working capital -621.80M -77.05M 19.04M 6.34M 15.72M
Stock based compensation 346.17M 289.03M 199.63M 217.78M 564.96M
Other non cash items -80.16M -708.77M -5237.17M 33.45M -334.29M
Free cash flow -758.56M -844.05M -766.65M -856.08M -695.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ROIV
Roivant Sciences Ltd		 0.66
1.60%		 41.85 - - 3788.07 7.00 3437.97 0.74
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Roivant Sciences Ltd

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

50 Broadway, London, United Kingdom, SW1H 0DB

44 20 7400 3347

https://roivant.com

721

Name Title Year Born
Mr. Vivek Ramaswamy Founder & Chairman 1985
Mr. Matthew Gline CEO & Director 1984
Dr. Eric Venker M.D., Pharm.D. Pres & COO 1987
Dr. Mayukh Sukhatme M.D. Pres & Chief Investment Officer 1976
Mr. Richard Pulik Chief Financial Officer 1979
Ms. Rakhi Kumar Chief Accounting Officer 1980
Dr. Huafeng Xu Ph.D. Chief Technology Officer NA
Mr. Josh Chen Gen. Counsel NA
Ms. Kelly Graff Head of People NA
Ms. Marianne L. Romeo Head of Global Transactions & Risk Management 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…